GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to
evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally
recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). After the interim analysis,
the design was changed to an open label, single arm study with all subjects receiving
pazopanib.